KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Long-Term Debt Repayments (2016 - 2026)

Gilead Sciences filings provide 17 years of Long-Term Debt Repayments readings, the most recent being $8.0 million for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments rose 14.29% to $8.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 billion, a 9.24% decrease, with the full-year FY2025 number at $1.8 billion, down 9.24% from a year prior.
  • Long-Term Debt Repayments hit $8.0 million in Q4 2025 for Gilead Sciences, down from $9.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $2.5 billion in Q3 2021 to a low of $7.0 million in Q4 2024.
  • Median Long-Term Debt Repayments over the past 5 years was $1.0 billion (2021), compared with a mean of $942.9 million.
  • Biggest five-year swings in Long-Term Debt Repayments: surged 150.0% in 2021 and later tumbled 99.51% in 2025.
  • Gilead Sciences' Long-Term Debt Repayments stood at $1.0 billion in 2021, then changed by 0.0% to $1.0 billion in 2022, then surged by 125.0% to $2.2 billion in 2023, then crashed by 99.69% to $7.0 million in 2024, then grew by 14.29% to $8.0 million in 2025.
  • The last three reported values for Long-Term Debt Repayments were $8.0 million (Q4 2025), $9.0 million (Q3 2025), and $9.0 million (Q2 2025) per Business Quant data.